Please select the option that best describes you:
Topics:
Breast Cancer • Medical Oncology • HR+ • Breast Cancer, Metastatic • hormone receptor positive • SABCS 2025
In what clinical scenarios, if any, would you consider using sacituzumab govitecan prior to trastuzumab deruxtecan for HR+/HER2- metastatic breast cancer treatment?
ASCENT-07 data recently did not meet the endpoint for progression-free survival for sacituzumab govitecan as a first-line treatment post-endocrine therapy in HR+/HER2-negative metastatic breast cancer compared to other chemotherapies.
Answer from: Medical Oncologist at Academic Institution
The ASCENT-07 trial did not meet the primary endpoint of superior PFS for 1st-line SG vs standard chemotherapy (taxane or capecitabine) in ER+ HER2- mBC. OS readout was immature with an early trend in favor of SG that needs follow-up. However, SG was still active with longer durations of responses. ...
Sign In or Register to read more